IRVING, Texas, April 13, 2010 (GLOBE NEWSWIRE) -- Caris Life Sciences™, a leading biosciences company focused on enabling precise and personalized healthcare, today announced the launch of its urologic pathology practice, available through its subsidiary Caris Diagnostics. The addition of this subspecialty, which is being directed by Rajal B. Shah, M.D., underscores Caris' commitment to providing high quality, academic-caliber diagnostic and theranostic services to a broadening list of subspecialties. Under Dr. Shah's leadership, Caris' urologic pathology experts will also support the development of a revolutionary and proprietary testing platform that will help diagnose and manage prostate cancer patients earlier and less invasively.
"Caris' commitment to precise and personalized healthcare begins with investment in subspecialty physician expertise. Our urologic pathology services will mirror our other subspecialty practices with a commitment to academic activities, including research and education, combined with unsurpassed service and the latest evidence-based molecular testing," said Richard H. Lash, M.D., Chief Medical Officer of Caris Life Sciences. "We are honored that Dr. Shah will be leading these efforts, bringing a distinguished academic record to Caris."
Dr. Shah, who joined the company in January of 2010, as previously announced, has been named Director of Caris' Urologic Pathology Services. Dr. Shah joined Caris from the University of Michigan where he served as Clinical Associate Professor of Urology and Pathology, as well as Director of the Urologic Pathology Service and Fellowship Program.
Dr. Shah has been published in more than 90 peer-reviewed journal publications, speaks frequently at both national and international venues, and has been the recipient of several NIH-funded grants. In 2007, Dr. Shah was part of a group of scientists awarded the inaugural "Team Science Award" from the American Association of Cancer Research for the discovery of recurrent gene fusions in prostate cancer. The Consumers' Research Council of America has selected Dr. Shah as one of America's Top Physicians.
The comprehensive diagnostic services offered by the Caris Urologic Pathology Department include multiplex immunohistochemistry (IHC), full-service molecular diagnostics, PCA3 testing (molecular urine assay for aiding prostate cancer detection), and expert second opinion diagnostic services. More information is available at http://www.carislifesciences.com/urology.
About Caris Life Sciences
Caris Life Sciences, a leading biosciences company, specializes in the development and commercialization of the highest quality anatomic pathology, molecular profiling, and blood-based diagnostic technologies, in the fields of oncology, dermatopathology, hematopathology, gastrointestinal pathology and urologic pathology. The company provides academic-caliber consultations through its industry-leading team of expert, subspecialty pathologists. Caris also offers advanced molecular analyses of patient samples through prognostic testing services and genomic, transcriptomic, and proteomic profiling to assist physicians in their treatment of cancer and other complex diseases. Biopsies from thousands of patients are received daily from physicians throughout the U.S., for analysis by Caris. Founded in 1996, the company is headquartered in Irving, Texas, and operates laboratories at the headquarters, as well as in Phoenix, Arizona and Newton, Massachusetts. More information is available at www.carislifesciences.com.